KU-0059436 (AZD2281)(PARP inhibitor)

DRUG7 trials

Conditions

Advanced Ovarian CancerAdvanced Solid MalignanciesBRCA1 ProteinBRCA2 ProteinCarboplatinMalignant Solid TumorsMelanoma NeoplasmsOvarian Neoplasm

Phase 1

Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer

CompletedNCT00515866

AstraZenecaPancreatic Neoplasms

Start: 2007-08-31End: 2012-07-31Updated: 2013-12-20

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine

CompletedNCT00516802

AstraZenecaMelanoma Neoplasms

Start: 2007-01-31End: 2009-01-31Updated: 2009-05-15

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

CompletedNCT00516724

AstraZenecaAdvanced Ovarian Cancer, Carboplatin, Paclitaxel +1

Start: 2007-06-22End: 2024-04-11Updated: 2025-04-11

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

CompletedNCT00516438

AstraZenecaMalignant Solid Tumors

Start: 2007-07-31End: 2009-11-30Target: 48Updated: 2010-12-08

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

CompletedNCT00516373

AstraZenecaBRCA1 Protein, BRCA2 Protein, Ovarian Neoplasms

Start: 2005-07-11End: 2023-04-26Updated: 2024-02-22

Open Label, Dose Escalation Phase I Study of AZD2281

CompletedNCT00572364

AstraZenecaAdvanced Solid Malignancies

Start: 2007-11-30End: 2009-06-30Target: 18Updated: 2009-08-20

Phase 2

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

CompletedNCT00494442

AstraZenecaOvarian Neoplasm

Start: 2007-06-11End: 2017-07-20Updated: 2018-08-01

2019-10-3014 citations

Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).

2019-10-2115 citations

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial

Trials2016-06-2118 citations

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.

2016-03-08125 citations

Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.

2015-01-0777 citations

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.

2013-01-01140 citations

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

2010-07-061030 citations

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

2009-06-242752 citations

KU-0059436 (AZD2281)(PARP inhibitor)

Sponsors

Conditions

Phase 1

Phase 2

Related Papers